文献速递神经免疫

继发进展型多发性硬化临床试验结局指标的可靠性

Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis.
PubMed 文献 · Neurology · 2020-10-26

该研究比较IMPACT与ASCEND两项随机对照试验安慰剂组中EDSS、T25FW、9HPT及其组合的进展与改善事件频率,发现EDSS改善率最高且进展与改善差值最小,T25FW与9HPT改善率稳定在10%左右或以下。所有指标均存在随机变异和测量误差,T25FW与9HPT较EDSS更少。

要点

  • EDSS在SPMS试验中改善率最高,进展与改善差值最小。
  • T25FW与9HPT改善率稳定,多低于或约10%。
  • 所有结局指标均存在随机变异,EDSS测量误差更明显。

核心结论

  • SPMS所有研究结局指标均显示随机变异和测量误差证据,T25FW与9HPT较EDSS更少。

研究设计与样本

  • 基于IMPACT和ASCEND两项SPMS大型RCT安慰剂组的原始试验数据,比较不同临床结局指标的进展与改善事件频率。

主要发现

  • 两个数据集中EDSS随时间改善率最高,进展与改善率差异最小,其次为T25FW和9HPT。
  • T25FW和9HPT改善率随时间较稳定,保持在10%以下或约10%水平。
  • EDSS改善率与残疾进展率平行增加。

关键数值与推荐

  • 比较了有无3个月或6个月确认的残疾进展及类似定义的改善,指标包括EDSS、T25FW、9HPT及其组合。

临床怎么用

  • 结果对SPMS试验设计及批判性评价具有参考价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the reliability of clinical outcomes in secondary progressive multiple sclerosis (SPMS) trials, we compared the frequency of progression and improvement events on different clinical outcome measures in the placebo arms of 2 large randomized controlled trial (RCT) datasets. METHODS: Using original trial data from the placebo arms of IMPACT (International MS Secondary Progressive Avonex Controlled Trial) and ASCEND (A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis), 2 large RCTs in SPMS, we compared disability progression and similarly defined improvement with and without 3- or 6-month confirmation on the outcome measures Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test (9HPT), and their combinations. RESULTS: In both datasets, the EDSS showed the highest rates of improvement over time, and the smallest difference between progression and improvement rates, followed by the T25FW and the 9HPT. For the T25FW and 9HPT, improvement rates were fairly stable over time and remained at below or around the 10% level. For the EDSS, improvement rates increased in parallel with disability progression rates. CONCLUSIONS: All investigated outcome measures in SPMS showed some evidence of random variation and measurement error, the T25FW and 9HPT less so than the more established outcome EDSS. Our findings are relevant for the design and critical appraisal of trials in SPMS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Koch MW, Mostert J, Repovic P, et al. Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. Neurology. 2020. PMID: 33106389. doi:10.1212/WNL.0000000000011123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。